SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium–glucose co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurgle, Holly E, White, Karen, McAdam-Marx, Carrie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902150/
https://www.ncbi.nlm.nih.gov/pubmed/27350752
http://dx.doi.org/10.2147/VHRM.S83088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902150/
https://www.ncbi.nlm.nih.gov/pubmed/27350752
http://dx.doi.org/10.2147/VHRM.S83088

Ejemplares similares